← Eichor
Condition: Acute Myeloid Leukemia With Flt3 Itd Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Acute Myeloid Leukemia With Flt3 Itd Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in
Phase 2 · 20 location(s) · French Innovative Leukemia Organisation · NCT06022003SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurren
Phase 1 · 4 location(s) · Uma Borate · NCT06222580Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete
Phase 2 · 58 location(s) · Daiichi Sankyo · NCT06824168Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05024552Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07259707A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
Phase 1 · 1 location(s) · Shijiazhuang Yiling Pharmaceutical Co. Ltd · NCT07162116
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.